Liesbeth Everix , Franziska Zajicek , Annemie Van Eetveldt , Longbin Liu , Jonathan Bard , Steven Staelens , Daniele Bertoglio
{"title":"zQ175DN小鼠亨廷顿病模型突触密度变化的评估:一项[18F]SynVesT-1研究","authors":"Liesbeth Everix , Franziska Zajicek , Annemie Van Eetveldt , Longbin Liu , Jonathan Bard , Steven Staelens , Daniele Bertoglio","doi":"10.1016/j.nicl.2025.103800","DOIUrl":null,"url":null,"abstract":"<div><div>Huntington’s disease (HD) is a neurodegenerative disorder characterized by involuntary movements, cognitive decline and psychiatric problems. HD has been associated with synaptic dysfunction and loss of the synaptic vesicle protein 2A (SV2A). SV2A can readily be quantified via positron emission tomography (PET) using the selective and high affinity SV2A radiotracer [<sup>18</sup>F]SynVesT-1 that we previously characterized in C57BL/6J mice. Here, we performed dynamic [<sup>18</sup>F]SynVesT-1 PET to characterize SV2A levels at various disease stages in another HD mouse model, zQ175DN, at 3 and 6 months (M) (longitudinal) and 10 M and 16 M (cross-sectional). We also conducted <em>ex vivo</em> SV2A immunofluorescent staining and [<sup>3</sup>H]UCB-J and [<sup>3</sup>H]SynVesT-1 autoradiography at 16 M. Dynamic [<sup>18</sup>F]SynVesT-1 PET revealed comparable <em>V</em><sub>T(IDIF)</sub> values between male and female 3 M and 6 M old zQ175DN mice. A significant age effect was found in the motor cortex and hippocampus between 3 M and 6 M. From 3 M to 10 M, no significant difference was found between heterozygous and wild-type mice. At 16 M, however, significant <em>V</em><sub>T(IDIF)</sub> differences were observed between genotypes in the motor cortex (−9.1 ± 3.5 %, <em>p</em> = 0.038), hippocampus (−7.5 ± 3.3, <em>p</em> = 0.036) and thalamus (−8.9 ± 3.1 %, <em>p</em> = 0.016). <em>Ex vivo</em> analyses did not confirm the observed deficits at 16 M, likely due to the decreased sensitivity compared to PET. However, [<sup>3</sup>H]SynVesT-1 and [<sup>3</sup>H]UCB-J autoradiography displayed the same outcome, ruling out a radioligand-specific effect. [<sup>18</sup>F]SynVesT-1 PET identified mild SV2A deficits in the zQ175DN model of HD at 16 M, whereas no significant SV2A deficits were detected at younger ages.</div></div>","PeriodicalId":54359,"journal":{"name":"Neuroimage-Clinical","volume":"46 ","pages":"Article 103800"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of changes in synaptic density in the zQ175DN mouse model of Huntington’s disease: a [18F]SynVesT-1 study\",\"authors\":\"Liesbeth Everix , Franziska Zajicek , Annemie Van Eetveldt , Longbin Liu , Jonathan Bard , Steven Staelens , Daniele Bertoglio\",\"doi\":\"10.1016/j.nicl.2025.103800\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Huntington’s disease (HD) is a neurodegenerative disorder characterized by involuntary movements, cognitive decline and psychiatric problems. HD has been associated with synaptic dysfunction and loss of the synaptic vesicle protein 2A (SV2A). SV2A can readily be quantified via positron emission tomography (PET) using the selective and high affinity SV2A radiotracer [<sup>18</sup>F]SynVesT-1 that we previously characterized in C57BL/6J mice. Here, we performed dynamic [<sup>18</sup>F]SynVesT-1 PET to characterize SV2A levels at various disease stages in another HD mouse model, zQ175DN, at 3 and 6 months (M) (longitudinal) and 10 M and 16 M (cross-sectional). We also conducted <em>ex vivo</em> SV2A immunofluorescent staining and [<sup>3</sup>H]UCB-J and [<sup>3</sup>H]SynVesT-1 autoradiography at 16 M. Dynamic [<sup>18</sup>F]SynVesT-1 PET revealed comparable <em>V</em><sub>T(IDIF)</sub> values between male and female 3 M and 6 M old zQ175DN mice. A significant age effect was found in the motor cortex and hippocampus between 3 M and 6 M. From 3 M to 10 M, no significant difference was found between heterozygous and wild-type mice. At 16 M, however, significant <em>V</em><sub>T(IDIF)</sub> differences were observed between genotypes in the motor cortex (−9.1 ± 3.5 %, <em>p</em> = 0.038), hippocampus (−7.5 ± 3.3, <em>p</em> = 0.036) and thalamus (−8.9 ± 3.1 %, <em>p</em> = 0.016). <em>Ex vivo</em> analyses did not confirm the observed deficits at 16 M, likely due to the decreased sensitivity compared to PET. However, [<sup>3</sup>H]SynVesT-1 and [<sup>3</sup>H]UCB-J autoradiography displayed the same outcome, ruling out a radioligand-specific effect. [<sup>18</sup>F]SynVesT-1 PET identified mild SV2A deficits in the zQ175DN model of HD at 16 M, whereas no significant SV2A deficits were detected at younger ages.</div></div>\",\"PeriodicalId\":54359,\"journal\":{\"name\":\"Neuroimage-Clinical\",\"volume\":\"46 \",\"pages\":\"Article 103800\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroimage-Clinical\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213158225000701\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROIMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimage-Clinical","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213158225000701","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROIMAGING","Score":null,"Total":0}
Assessment of changes in synaptic density in the zQ175DN mouse model of Huntington’s disease: a [18F]SynVesT-1 study
Huntington’s disease (HD) is a neurodegenerative disorder characterized by involuntary movements, cognitive decline and psychiatric problems. HD has been associated with synaptic dysfunction and loss of the synaptic vesicle protein 2A (SV2A). SV2A can readily be quantified via positron emission tomography (PET) using the selective and high affinity SV2A radiotracer [18F]SynVesT-1 that we previously characterized in C57BL/6J mice. Here, we performed dynamic [18F]SynVesT-1 PET to characterize SV2A levels at various disease stages in another HD mouse model, zQ175DN, at 3 and 6 months (M) (longitudinal) and 10 M and 16 M (cross-sectional). We also conducted ex vivo SV2A immunofluorescent staining and [3H]UCB-J and [3H]SynVesT-1 autoradiography at 16 M. Dynamic [18F]SynVesT-1 PET revealed comparable VT(IDIF) values between male and female 3 M and 6 M old zQ175DN mice. A significant age effect was found in the motor cortex and hippocampus between 3 M and 6 M. From 3 M to 10 M, no significant difference was found between heterozygous and wild-type mice. At 16 M, however, significant VT(IDIF) differences were observed between genotypes in the motor cortex (−9.1 ± 3.5 %, p = 0.038), hippocampus (−7.5 ± 3.3, p = 0.036) and thalamus (−8.9 ± 3.1 %, p = 0.016). Ex vivo analyses did not confirm the observed deficits at 16 M, likely due to the decreased sensitivity compared to PET. However, [3H]SynVesT-1 and [3H]UCB-J autoradiography displayed the same outcome, ruling out a radioligand-specific effect. [18F]SynVesT-1 PET identified mild SV2A deficits in the zQ175DN model of HD at 16 M, whereas no significant SV2A deficits were detected at younger ages.
期刊介绍:
NeuroImage: Clinical, a journal of diseases, disorders and syndromes involving the Nervous System, provides a vehicle for communicating important advances in the study of abnormal structure-function relationships of the human nervous system based on imaging.
The focus of NeuroImage: Clinical is on defining changes to the brain associated with primary neurologic and psychiatric diseases and disorders of the nervous system as well as behavioral syndromes and developmental conditions. The main criterion for judging papers is the extent of scientific advancement in the understanding of the pathophysiologic mechanisms of diseases and disorders, in identification of functional models that link clinical signs and symptoms with brain function and in the creation of image based tools applicable to a broad range of clinical needs including diagnosis, monitoring and tracking of illness, predicting therapeutic response and development of new treatments. Papers dealing with structure and function in animal models will also be considered if they reveal mechanisms that can be readily translated to human conditions.